about
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.Safety of therapeutic doses of tinzaparin during pregnancy.Prediction of pulmonary embolism in the emergency department: the revised Geneva score.Laboratory tests in the diagnosis of pulmonary embolism.Molecular diagnosis of Kingella kingae pericarditis by amplification and sequencing of the 16S rRNA genePERC rule to exclude the diagnosis of pulmonary embolism in emergency low-risk patients: study protocol for the PROPER randomized controlled study.Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review.Long-term outcome of pulmonary embolism.Pulmonary arterial hypertension in women.Pulmonary embolism during pregnancy: diagnosis with lung scintigraphy or CT angiography?Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.Management of massive and submassive pulmonary embolism: focus on recent randomized trials.Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial.Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.Pulmonary embolism: whom to discharge and whom to thrombolyze?Fibrinolysis for Acute Care of Pulmonary Embolism in the Intermediate Risk Patient.Risk assessment and management of high and intermediate risk pulmonary embolism.From Acute to Chronic Thromboembolic Disease.Outpatient management of pulmonary embolism.Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embolism.Very Small Embryonic-like Stem Cells Are Mobilized in Human Peripheral Blood during Hypoxemic COPD Exacerbations and Pulmonary Hypertension.Pathophysiology of dyspnoea in acute pulmonary embolism: A cross-sectional evaluation.A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.Knowledge of the diagnostic algorithm for pulmonary embolism in primary care.Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation.[Guidelines for the diagnosis and treatment of pulmonary hypertension].Identification of intermediate-risk patients with acute symptomatic pulmonary embolism.[Pulmonary hypertension associated with connective tissue diseases].[Acute complications in cocaine users].Successful retrieval of 29 ALN inferior vena cava filters at a mean of 25.6 months after placement.[Pulmonary artery hypertension associated with connective tissue diseases].Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism.Outcome of patients with interstitial lung disease admitted to the intensive care unit.[Pulmonary arterial hypertension in women].Pulmonary hypertension associated with benfluorex exposure.Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.Half the family members of intensive care unit patients do not want to share in the decision-making process: a study in 78 French intensive care units.Tinzaparin and VKA use in patients with cancer associated venous thromboembolism: a retrospective cohort study.Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism.
P50
Q33144907-93D8FCB3-E78C-466B-8FAB-DF491E4F50FCQ33422194-E37BD4AE-4B68-4B91-A967-5429E6C3EFC1Q34492103-116E8C11-B8BE-4752-A127-910B15B9B8ADQ35124957-1A317EB2-194A-4455-A614-CC389EDCF8C1Q36098643-D9AB0A50-7DE3-42D1-95DF-EC0814921890Q36321868-9AE4F3D8-0DE6-43C1-A2DD-23DF39F0B573Q37170044-48401DAE-0D09-49C7-A668-532F1C075AB6Q37241537-6F5840CC-841B-4E4C-B340-3E7DFE7B0185Q37802035-58328712-0222-41EA-8AE0-513CE7A0C953Q37816042-73C976A3-F41F-4B69-A6EB-70B559C1F05BQ38219389-99A9ADE6-8451-4855-995D-289970E994CBQ38230119-B97909FF-D178-4472-AA85-967E432E4CB2Q38396359-47AD1E18-427F-4690-8433-83FC186C1BDCQ38408533-2C893BE5-B81B-4AB0-977F-74A4AEA34749Q38434158-B1C3621E-7452-4651-816B-63732ECB43F4Q38543299-BF0784BF-D77C-4338-A149-2A4C0A018F14Q38612584-5B526063-39E2-4206-A349-97583177D60CQ38639180-82ADD7A4-8294-4CF2-A7C1-C899AB3D6301Q38826925-FFBD7795-5C34-424D-A007-9165F010239DQ39318431-6D63F346-3686-4497-8448-092715CB361EQ40253319-4487AEE5-EBEC-4975-A54A-65B0E000FCA6Q40297970-5A2EEAD7-73BC-4408-9955-921AE5DD236EQ40457500-F103E694-210A-4916-92E2-8462821719AFQ41435645-B3F1E8EF-A481-46C2-9819-B69275C79227Q41700901-8FD5F3C0-5EC8-461F-91C8-5AEDDBDF3728Q43136274-B01B17B3-45CE-4BE1-8625-1A3F890231CBQ43141520-25AFE835-14A6-44D4-A6A5-58BCA0A6F7FCQ43674500-75C62784-37CD-4FFE-945F-D935342D4A31Q43891962-5CB68079-F764-4E2B-A2BA-36E16587582EQ44129977-2BE1F44F-34A8-44BB-A4E0-EA47B5D2B2EAQ44391572-8D27FE9E-42E1-4F92-AEA1-4C0D74CD995AQ44510220-F20BDAAC-BAC7-4DC0-9C85-A6909B323E6DQ44813865-140DA0B4-2F93-4391-B05E-29C8535A9237Q46153304-CC080953-EE62-4B23-82B8-A35D5B1EB2F7Q46554011-FA2193E7-740F-4139-A3C7-16B24E9DCA0BQ46604185-262001F2-172D-477D-B462-57DAB6DDD6AEQ47939603-775FC13E-6B80-43DA-98C7-D14DC0EA7968Q50993508-697C1773-B278-4C33-9B48-502E3388F944Q51028703-A64AF747-EF51-4C07-849F-58361F238257Q51081378-F651D0A7-3E84-4117-ABA1-9FB97962DB72
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Olivier Sanchez
@ast
Olivier Sanchez
@en
Olivier Sanchez
@es
Olivier Sanchez
@nl
type
label
Olivier Sanchez
@ast
Olivier Sanchez
@en
Olivier Sanchez
@es
Olivier Sanchez
@nl
prefLabel
Olivier Sanchez
@ast
Olivier Sanchez
@en
Olivier Sanchez
@es
Olivier Sanchez
@nl
P106
P31
P496
0000-0003-1633-8391